SARS
This article was originally published in The Gray Sheet
Executive Summary
Intercept blood system for platelets and red blood cells inactivates the causative agent of severe acute respiratory syndrome, according to Cerus. Intercept, which is approved in Europe, was delayed approval by FDA in June due to an agency request for additional clinical data (1"The Gray Sheet" June 9, 2003, p. 23). No known cases of SARS have yet been reported via blood transfusion, according to the Centers for Disease Control & Prevention...